Syndax Pharmaceuticals (SNDX) Enterprise Value (2015 - 2026)

Syndax Pharmaceuticals' Enterprise Value history runs 12 years deep, the most recent figure standing at -$352.1 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 122.67% year-over-year to -$352.1 million; the TTM figure through Mar 2026 stood at -$352.1 million (down 122.67% YoY), while the FY2025 annual figure was -$394.1 million, down 140.12% from the prior year.
• Enterprise Value was -$352.1 million for Q1 2026 at Syndax Pharmaceuticals, up from -$394.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$74.5 million in Q4 2022 to a low of -$570.7 million in Q4 2023.
• Historically, Enterprise Value has averaged -$311.7 million across 5 years, with a median of -$363.6 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value sank 666.34% in 2023, then jumped 71.77% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$74.5 million in 2022, then tumbled by 666.34% to -$570.7 million in 2023, then surged by 71.24% to -$164.1 million in 2024, then tumbled by 140.12% to -$394.1 million in 2025, then grew by 10.66% to -$352.1 million in 2026.
• The last three Enterprise Value figures came in at -$352.1 million (Q1 2026), -$394.1 million (Q4 2025), and -$135.0 million (Q3 2025), per Business Quant data.